Skip to main content
POOLBEG PHARMA PLC logo

POOLBEG PHARMA PLC — Investor Relations & Filings

Ticker · POLB ISIN · GB00BKPG7Z60 LEI · 213800UZ8WJLWYHBFL52 IL Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2022-03-31 Regulatory Filings
Country GB United Kingdom
Listing IL POLB

About POOLBEG PHARMA PLC

https://poolbegpharma.com/

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that develops and commercializes medicines for diseases with high unmet medical needs. The company's lead asset, POLB 001, is a treatment designed to prevent Cytokine Release Syndrome (CRS), a severe side effect associated with cancer immunotherapies, with the aim of making these treatments safer and more accessible. Poolbeg is also advancing an oral GLP-1 program for obesity, offering a patient-friendly therapeutic option. The company utilizes an artificial intelligence (AI)-led discovery platform that analyzes data from human challenge trials to identify novel drug targets. This AI-driven approach aims to accelerate target identification, reduce costs, and lower development risks.

Recent filings

Filing Released Lang Actions
POLB001 Update - Clinical Trial Agreement Signed
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 6800G' and explicitly states, 'The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.' The content details a specific operational update (signing a Clinical Trial Agreement for POLB 001) and concludes with RNS boilerplate information. This structure strongly indicates a general regulatory news service announcement, which maps directly to the 'Regulatory Filings' category (RNS), as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG).
2022-03-31 English
Commencement of trading on US OTCQB market
Regulatory Filings Classification · 1% confidence The document is an official announcement released via RNS (RNS Number: 4724G) on March 30, 2022. The core subject is the commencement of trading of Poolbeg Pharma PLC's Ordinary Shares on the OTCQB Venture Market in the United States, including details about the ticker (POLBF), the lack of a capital raise, and compliance with the Rule 12g3-2(b) exemption. This type of announcement, which communicates a specific corporate action or event update through a regulatory news service, fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific filing like a Director's Dealing (DIRS) or Proxy Statement (PSI). Since it is a general regulatory news service release that doesn't fit a more specific operational code, RNS is the appropriate classification.
2022-03-30 English
AI deal signed with CytoReason
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '24 March 2022'. It announces a specific corporate event: 'Poolbeg Pharma PLC... Artificial Intelligence deal signed with CytoReason'. The text is structured as a press release detailing a business development (a partnership/deal) and includes quotes from management and contact information for brokers and PR firms. This format strongly indicates a regulatory news service announcement. Since it is a general announcement of a significant business event (a deal) that doesn't fit perfectly into specific financial report categories (like 10-K, ER, or DIV), the most appropriate classification is the general regulatory announcement category, RNS (Regulatory Filings). The document length (10,318 chars) is substantial enough that it is the announcement itself, not just a brief notice pointing to an attachment.
2022-03-24 English
Notice of AGM
AGM Information Classification · 1% confidence The document explicitly states it announces the release of the '2021 Annual Report and Accounts for the period ended 31 December 2021' AND a 'notice of the Annual General Meeting ("AGM") 2022'. Since it contains both the full Annual Report information (covering the full fiscal year) and the AGM notice/proxy information, it is a composite filing. However, the primary regulatory filing for the full year's performance is the Annual Report (10-K equivalent in structure, though this is likely a UK AIM filing). Given the explicit mention of the 'Annual Report and Accounts' and the AGM notice, the most encompassing and significant classification is the Annual Report (10-K), as the AGM notice is often bundled or closely related to the annual reporting cycle. If a specific 'Annual Report' code existed separate from 10-K, that would be preferred, but 10-K serves as the best proxy for the comprehensive annual filing. The document length (7250 chars) is substantial enough to contain the report details, not just an announcement of publication (RPA).
2022-03-09 English
Final Results
Report Publication Announcement Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Poolbeg Pharma PLC. It provides a summary of financial results for the period ended 31 December 2021, including operational highlights, financial highlights, and a Chairman's statement. Crucially, the text explicitly states: 'The Company's Annual Report and Accounts for the period ended 31 December 2021 will be posted to shareholders in due course... and will be available on the Company's website'. This confirms the document is an announcement of the report's upcoming publication rather than the full Annual Report itself. Therefore, it falls under the 'Report Publication Announcement' (RPA) category. FY 2021
2022-03-03 English
Notice of Results
Report Publication Announcement Classification · 1% confidence The document is very short (4229 characters) and its primary purpose is to announce that the company 'will announce its results for the period ended 31 December 2021 on Thursday 3 March 2022.' It also mentions an accompanying investor presentation. This structure—announcing the future release of results rather than containing the results themselves—fits the definition of a Report Publication Announcement (RPA). The presence of the RNS Number and the footer referencing RNS confirms it is a regulatory announcement, but RPA is more specific than the general RNS fallback because it explicitly concerns the publication timing of another report (the results).
2022-02-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.